Overview

Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition

Status:
Completed

Trial end date:
2020-11-25

Target enrollment:

Participant gender:

Summary

Single oral administration of study drugs (i.e. Anplag® & Brilinta®) in Two periods after at least 10 hours fasting. The periods will be separated by a washout period of 7 days. The purpose of this study is to compare the bioavailability of Anplag® 90mg (Ticagrelor) Tablet with Brilinta® 90 mg (Ticagrelor) Tablet under fasting conditions in healthy Pakistani male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

University of Karachi

Collaborator:

PharmEvo Private Limited., Pakistan

Treatments:

Ticagrelor